Global prevalence of advanced fibrosis in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis

Abstract

AbstractBackground and AimPatients with type 2 diabetes mellitus (T2DM) face a heightened susceptibility to advanced fibrosis, a condition linked to adverse clinical outcomes. However, reported data on liver fibrosis severity among individuals with T2DM vary significantly across studies with diverse characteristics. This meta‐analysis aimed to estimate the global prevalence of advanced fibrosis among T2DM patients.MethodsA comprehensive systematic search of the EMBASE and MEDLINE databases from inception to November 2022 was conducted to identify studies assessing advanced fibrosis in individuals with T2DM. Random‐effects models were utilized to calculate point estimates of prevalence, accompanied by 95% confidence interval (CI). Meta‐regression with subgroup analysis was employed to address heterogeneity.ResultsWe identified 113 eligible studies involving 244,858 individuals from 29 countries. Globally, the prevalence of advanced fibrosis among T2DM patients was 19.5% (95% CI 16.8–22.4%). Regionally, the prevalence rates were as follows: 60.5% in West Asia (95% CI 50.3–70.4%), 24.4% in South Asia (95% CI 16.2–33.7%), 20.1% in East Asia (95% CI 14.7–26.1%), 20.0% in Europe (95% CI 15.8–24.6%), 15.8% in North America (95% CI 11.0–21.3%), and 11.3% in South America (95% CI 6.2–17.5%). The prevalence of advanced fibrosis varied notably based on the study setting and diagnostic methodology employed. Meta‐regression models highlighted that 45.13% of the observed heterogeneity could be attributed to combined diagnostic modality and study setting.ConclusionsGlobally, approximately one fifth of the T2DM population presents advanced fibrosis, with prevalence differing across geographical regions. Our findings underscore the need for effective strategies to alleviate its global burden.